Deficiencies of early components of the classical complement pathway are known to be associated with systemic lupus erythematosus (SLE). C4 null alleles, C4A QO and C4B QO, are prime candidates for the major histocompatibility complex associated factor which determines susceptibility to SLE. There is poor correlation, however, between the presence of low concentrations of C4 and possession of C4 null alleles, and thus the basis of the association between C4A QO, C4B QO and SLE remains obscure. The possibility that activation of C4 may be related to the possession of C4 null alleles was examined. C4 phenotypes were investigated, and C4 concentration and activation were estimated in patients with SLE. C4 activation was determined by measuring the concentration of C4d-a split product of C4. 
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Discussion
This study shows that C4 null alleles, prime candidates for the MHC associated factor which confers susceptibility to SLE,20 are associated with impaired activation of the C4 molecule.
The prevalence of C4 null alleles in patients with SLE has been shown to be high,'1-8 24 and our observations are consistent with this.
We suggested that a defect in C4 activation might be of pathogenetic relevance in SLE and explored this in relation to C4 null alleles. In this paper we present data showing that in SLE the degree of C4 activation, as indicated by the concentration of C4d, is indeed dependent on C4 null alleles, being reduced in patients with null phenotypes. This implies an influence on C4 activation by C4 genes, which cannot be explained by an association of C4 null alleles with low C4 concentrations because, firstly, low C4 concentrations were not associated with C4 null phenotypes, and, secondly, C4d concentrations were unrelated to the concentrations of C4. We think it unlikely that the association between low C4 activation and C4 null alleles is due to linkage disequilibrium between C4 null genes and a locus encoding factors regulating C4 activation because Cl proteins, which directly activate C4,' are determined by genes on chromosomes 1 and 12,25 26 and no other relevant genes are found in the MHC.
A current theory to explain the susceptibility to SLE conferred by the inheritance of null between C4 activation and possession of C4 null alleles in patients with SLE. Further investigation is required to understand whether this is specific to this disease or applies equally to disorders such as systemic sclerosis,27 28 which are also characterised by accelerated C4 turnover and increased prevalence of C4 null alleles. 
